This marks the first step in a global application process, which will be followed by applications in the USA, among other countries.

"H199/18 is the first PPI synthesised as an isomer to be available for clinical use, and it is a further evolution in PPI therapy beyond omeprazole", said Dr Martin Nicklasson, Executive Vice President of AstraZeneca's GI Franchise. "This is a significant milestone for AstraZeneca's business in the gastrointestinal area."